Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials.
about
Interferon alpha for the adjuvant treatment of cutaneous melanomaInterferon alpha for the adjuvant treatment of cutaneous melanomaCharacterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanomaSkin mapping with punch biopsies for defining margins in melanoma: when you don't know how far to goAnal melanomaSonography of the primary cutaneous melanoma: a reviewCritical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma.Utility of adjuvant systemic therapy in melanoma.State of melanoma: an historic overview of a field in transition.Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III diseaseAdjuvant radiation therapy in metastatic lymph nodes from melanoma.IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosisNoninterferon-based adjuvant therapy for high-risk melanoma.Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha.Melacine: an allogeneic melanoma tumor cell lysate vaccine.Trends in the treatment and survival for local and regional cutaneous melanoma in a US population-based study.Systematic review of medical treatment in melanoma: current status and future prospects.The relation between c-myc expression and interferon sensitivity in uveal melanoma.Adjuvant therapy: melanomaAdjuvant therapy for malignant melanoma.Emerging melanoma vaccines.U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma.Immunotherapy for melanoma: current status and perspectives.Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approachAdjuvant therapy of melanoma with interferon: lessons of the past decadeCurrent clinical overview of cutaneous melanoma.Metastatic melanoma - a review of current and future drugsHuman interferon alpha-2b: a therapeutic protein for cancer treatmentThe combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.Cell-type and donor-specific transcriptional responses to interferon-alpha. Use of customized gene arrays.Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial.Biological Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated With GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma.Sentinel node biopsy has no benefit for patients whose primary cutaneous melanoma has metastasized to a lymph node and therefore should be abandoned now.Urban-rural differences in survival from cutaneous melanoma in Queensland.Development of IFN-gamma resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS 3 in melanoma cells.Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease.Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma.Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients.[Malignant head and neck melanoma: Part 2: Therapy].
P2860
Q24201908-59554B47-F3A5-406B-8F71-9EDA940A3D35Q24235257-7A1F45CF-B52B-4BA6-8DDF-DDF75059E9A5Q24685552-785AD9B3-FA51-4D48-96B7-879124CFBA8FQ30436479-061395B6-F382-4F81-9160-50FEB3873ABAQ30437650-7FD6166A-B68E-41C6-938E-70155119E319Q30468180-D0C7DF7F-CE43-41E1-8386-8E928C44F59EQ33184877-D725E0EB-4FE1-49B1-B09A-1F7FC95824D2Q33484065-D17CC23C-56C6-4C25-9464-107C8D20783CQ33693906-2CEF4B9A-748B-4D08-8188-EC6C454E4F43Q34391496-F640A3FA-9F81-4C60-86E4-DFD13BACBCF5Q34585715-85CB3FE8-8319-4D62-B5C4-138FFFE223C5Q34598755-FC30A04F-59BF-4A1D-9CC3-87533F0328D3Q34969252-03DF3C74-DFCE-458B-9676-FD02AA0FA1F8Q35057739-723CEA53-0A95-4550-B528-A16F89DB4EC3Q35194168-3295AEE1-11D1-4F11-9D31-E23EE71013E1Q35528902-B002204F-E0CE-4D08-93D1-A4AFC0A33A42Q35584299-854C07F9-413E-4763-8266-39AD024E0856Q35592697-E07EB16B-E6E4-4EA2-9FE3-7205FADEFE74Q35636225-F3787B9F-E466-4A94-893D-31CD1817B510Q35918453-A106126B-FD99-498E-85F8-E22AD27A505EQ36150640-4F2C3D2C-E515-4E3A-9274-9C806B410186Q36349616-FB3B8D6E-7041-4D7D-AC3C-D4812426FD8FQ36453216-53A9BB4C-D202-4D51-81AC-7D9511A0B7C0Q36844314-DFD2899A-FA5C-4FB3-8CF0-CB0E986BCCC7Q37021067-9889094E-0A77-462D-9499-ABFDA06BBFDFQ37139142-96F113B7-4F54-498C-8F55-A6DC8DBB22E7Q37450733-D62B2F77-8CF7-4998-8793-C36D09C2CC98Q37668825-6B528C4B-5C20-40C2-B7EC-5C926AF66DB0Q37697141-0F473AD0-CBB7-4D30-842E-4FE21515ACD8Q38361837-A26C1532-98D4-45EA-B67E-58E70E96D27FQ38391496-1439513B-1DE8-468F-92F8-F8DAB2B173C6Q39118074-212AD6CD-E7F4-4161-AB2C-110F1EF3E80CQ39218240-9A88EAC3-CEF4-4278-9810-B8570FFC0B8EQ39747311-65A1AA9C-F80E-4801-AD41-E49F91EB2DC4Q40117652-6AA4EE76-E719-476D-9247-D795D074F654Q42673382-3437AFEF-7269-4346-BD75-9151CFC45DDFQ45183209-9A50C2B8-A050-4DD9-AABC-A79C31C26497Q50701417-5D5942C6-66D4-4737-8515-FF7A6B410A28Q52822549-35F78C16-8406-4769-BAC9-94C1370EEE2BQ54256327-F09D76CB-B047-4CFD-AAFE-22429AF0C303
P2860
Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Interferon alfa therapy for ma ...... randomized controlled trials.
@ast
Interferon alfa therapy for ma ...... randomized controlled trials.
@en
Interferon alfa therapy for ma ...... randomized controlled trials.
@nl
type
label
Interferon alfa therapy for ma ...... randomized controlled trials.
@ast
Interferon alfa therapy for ma ...... randomized controlled trials.
@en
Interferon alfa therapy for ma ...... randomized controlled trials.
@nl
prefLabel
Interferon alfa therapy for ma ...... randomized controlled trials.
@ast
Interferon alfa therapy for ma ...... randomized controlled trials.
@en
Interferon alfa therapy for ma ...... randomized controlled trials.
@nl
P356
P1476
Interferon alfa therapy for ma ...... randomized controlled trials.
@en
P2093
Marko B Lens
Martin Dawes
P304
P356
10.1200/JCO.2002.07.070
P407
P577
2002-04-01T00:00:00Z